A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

United States

Clinical Pharmacology of Miami, Miami, Florida

Phase

Safety & dosing

Sponsor

Hua Medicine Limited

Collaborators

TigerMed

Enrollment target

~40 participants

Started

December 2025

Primary completion

August 2026

Age range

18 Years – 65 Years

Last updated on clinicaltrials.gov in May 2026.

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Jesus Olivia

Hua Medicine Limited